Method for cancer immunotherapy
View Patent ↗A novel compound of the formula (1): wherein X is a tyrosine residue or a methionine residue; Y and Z each are a single bond or the like; R 1 is a hydrogen atom or the like; R 2 is a hydroxy group or the like; R 3 is a hydrogen atom, alkyl group, amino group or the like; R 4 is a hydrogen atom, alkyl group, carboxy group or the like; m is 1 or 2; and n is an integer of 0 to 2, with the proviso that when n is 0, R 3 is a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof, and its use in cancer immunotherapy.
1. A method for inducing CTLs, comprising:
treating a peripheral lymphocyte isolated from a subject with a compound of the formula (1):
wherein X is a tyrosine residue or a methionine residue,
each of Y and Z is independently selected from a single bond and a divalent peptide group consisting of 1-10 amino acid residues,
R 1 is hydrogen or alkyl,
R 2 is hydroxyl, amino, alkylamino or dialkylamino,
R 3 is hydrogen, alkyl, amino, alkylamino, dialkylamino or substituted or unsubstituted alkylcarbonylamino,
R 4 is hydrogen, alkyl, carboxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or a group of the formula (2):
wherein W is an amino acid residue,
m is 1 or 2, and
n is an integer of 0 to 2, with the proviso that when n is 0, R 3 is hydrogen or alkyl,
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein X is a tyrosine residue.
3. The method of claim 1 , wherein X is a methionine residue.
4. The method of claim 1 , wherein the compound is a compound of formula (4):
5. The method of claim 1 , wherein the compound is a compound of formula (5):